Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies

Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies

In GEMINI-1/-2, dolutegravir + lamivudine was non-inferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in achieving viral suppression (viral load [VL] < 50 copies/mL) in treatment-naive adults. Abbott’s RealTime HIV-1 assay provides quantitative VL (40–10,000,000 copie...

Full description

Bibliographic Details
Main Authors: Mark Underwood, Rimgaile Urbaityte, Ruolan Wang, Joe Horton, James Oyee, Brian Wynne, Dainielle Fox, Bryn Jones, Choy Man, Jörg Sievers
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Viruses
Subjects:
antiretroviral therapy
two-drug regimen
DTG + 3TC
HIV-1 infection
very-low-level viremia
virologic response
Online Access:https://www.mdpi.com/1999-4915/16/3/405

Internet

https://www.mdpi.com/1999-4915/16/3/405

Similar Items